Zentalis Pharmaceuticals, Inc. (ZNTL)
- Sector
- Biotechnology
- Last price
- $1.60
- As of
Kresmion compiles this page from ZNTL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Zentalis Pharmaceuticals, Inc. (ZNTL): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full ZNTL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZNTL on one page. Preview it with sample data, then open it live with a free account.
Preview the ZNTL dossierActive events for ZNTL
- high13F: large reduction
CITADEL ADVISORS LLC cut 96% of ZNTL (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 91% of ZNTL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +699% to ZNTL (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 63% of ZNTL (2026Q2)
- mediumEarnings below estimates
Q2-2026: Missed consensus by 18.1%, EPS $-0.59 vs $-0.4997 estimate
FREE, NO ACCOUNT
Every event on ZNTL, as it fires
You are seeing 5 of 11 events recorded on ZNTL since 2026-05-31.
The five above landed across 2 days. The other 6 were recorded on 3 other days. 6 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ZNTL positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 98943L107 · 2026Q3 | $4.2M | 0.01% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZNTL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on ZNTL
ZNTL against its peers
ZNTL's return on equity of -63.4% ranks in the 30th percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ZNTL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 12.0M USD | 3 | 16 |
| Gross margin | n/a | 64.3% | n/a | 9 |
| Operating margin | n/a | -599.8% | n/a | 17 |
| Net margin | n/a | -194.3% | n/a | 18 |
| Return on equity | -63.4% | -32.6% | 30 | 21 |
| 1 year | 20.3% | -13.9% | 63 | 22 |
Peers (23): NAGE, STRO, IVVD, BBOT, IFRX, ACOG, ANTX, ORMP, SION, IPHA, ELDN, TARA, FATE, ANIK, KROS, HUMA, SLGL, WHWK, UPB, MDWD, KRRO, ABEO, PYXS. Left out: SCNLD (no annual filing), VRXA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZNTL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ZNTL on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ZNTL in the last 180 days.
Upstream: SEC EDGAR filings for ZNTL
Kresmion, "Zentalis Pharmaceuticals, Inc. (ZNTL) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/ZNTL. Upstream data: SEC EDGAR filings for ZNTL.
Link to this data (HTML):
<a href="https://kresmion.com/research/ZNTL">Zentalis Pharmaceuticals, Inc. (ZNTL) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ZNTL on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ZNTL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.